The biggest pending merger in New Jersey – in fact, the biggest in the world – is Bristol-Myers Squibb’s $74 billion bid for Summit-based Celgene Corp., which is led by Alles. The deal is scheduled to close in the third quarter, putting Alles at the center of a major M&A story.
He certainly has the background to handle it. Alles became chief executive officer and joined the Celgene Board of Directors in March 2016. He was appointed chairman in 2018. He served as president and chief operating officer from 2014 until 2016, executive vice president and global head of Hematology & Oncology from 2012 until 2014. He was Celgene’s chief commercial officer and vice president, Global Hematology Marketing. In 2009 he was promoted to president of the Americas Region. In 2011, his responsibilities expanded to commercial operations in Japan and the Asia Pacific Region.
Before joining Celgene, he was vice president of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rhône-Poulenc Rorer) from 1993-2004. Alles began his 30-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson.